HeartBeam Announces Automated Cardiac Detection Patent Granted for HeartBeam AIMIGo™ System
25 Mai 2023 - 2:31PM
Business Wire
Patent Underscores AI for Vectorcardiography
(VECG) IP Leadership Effort
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology
company that has developed the first and only 3D vector
electrocardiogram (VECG) platform intended for patient use at home,
today announced it has received a notice of allowance from The
United States Patent and Trademark Office for a key patent relating
to the initial AI capability in the form of an expert system for
its HeartBeam AIMIGoTM System. The patent is entitled, “Hand Held
Device for Automatic Cardiac Risk and Diagnostic Assessment.”
HeartBeam has developed the HeartBeam AIMIGo System, a personal,
portable and easy-to-use VECG solution to assist patients and their
clinicians in assessing cardiac symptoms. HeartBeam’s breakthrough
solution employs a reusable, credit card-sized, VECG recording
device and cloud-based software to deliver critical data to
clinicians in real-time outside of a medical setting. More than 127
million people in the US have cardiovascular disease, including
more than 20 million with coronary artery disease.
“We believe this patent will further our effort to create a
dominant IP position in the area of ambulatory VECG. We believe
that coupling AI with the highest resolution ambulatory ECG device
available will have the power to deliver unprecedented diagnostic
capability for patients experiencing acute cardiac symptoms, which
will ultimately lead to improved care and saved lives,” said
Branislav Vajdic, PhD, HeartBeam CEO and founder.
“This patent will be followed by an aggressive IP development
effort with PatentVest as we refine our algorithms, systems and
devices,” added Vajdic.
The newly allowed patent describes a system that combines the
recorded cardiac signals from the HeartBeam AIMIGo VECG device with
the patient’s symptoms and cardiac risk factors to calculate a
cardiac risk score, providing simplified diagnostic information and
actionable instructions to the patient. It aims to replicate the
decision-making process a physician uses when assessing a patient
with cardiac symptoms but performed remotely in an automated
manner.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform
intended for patient use at home. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to assess their cardiac symptoms quickly and easily, so
care can be expedited, if required. HeartBeam has two patented
products in development. HeartBeam AIMI™ is software for acute care
settings that provides a 3D comparison of baseline and symptomatic
12-lead ECG to more accurately identify a heart attack. HeartBeam
AIMIGo™ is the first and only credit card-sized 12-lead output ECG
device coupled with a smart phone app and cloud-based diagnostic
software system to facilitate remote evaluation of cardiac
symptoms. HeartBeam AIMI and AIMIGo have not yet been cleared by
the US Food and Drug Administration (FDA) for marketing in the USA
or other geographies. For more information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230525005355/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact: media@heartbeam.com
HeartBeam (NASDAQ:BEAT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
HeartBeam (NASDAQ:BEAT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024